Search - tctmd.com

Displaying 261 - 280 of 426

Sort: Relevancy | Date

News Daily News

Stick-on Sensor Predicts Heart-Failure Hospitalizations: Pilot Study

Shelley Wood

February 26, 2020

News Daily News

MR Improves in Half of Low-Flow/Low-Gradient AS Patients Undergoing TAVR

Michael O'Riordan

February 13, 2020

News Daily News

Kidney Transplant Boosts CV Functional Reserve

Todd Neale

February 07, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Features

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

Shelley Wood

December 23, 2019

News Conference News AHA 2019

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

Shelley Wood

November 22, 2019

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

Todd Neale

November 17, 2019

News Conference News AHA 2019

ISCHEMIA: Invasive Strategy No Better Than Meds for CV Events

Shelley Wood

November 16, 2019

News Opinion Off Script AHA 2019

Off Script: Will ISCHEMIA Answer Our Most Pressing Questions?

Ajay Kirtane, MD, SM

November 12, 2019

News Industry News

Intact Vascular Announces Positive Six-Month Data from TOBA II BTK Clinical Trial During Late-Breaking Session at 2019 VIVA Conference

November 06, 2019

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

News Conference News TCT 2019

Portico Noninferior to Commercial TAVR Valves in IDE Study

Caitlin E. Cox

September 27, 2019

News Industry News

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

September 27, 2019

News Conference News HFSA 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

L.A. McKeown

September 16, 2019

News Conference News ESC 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Yael L. Maxwell

September 12, 2019

News Conference News ESC 2019

Stopped Early, DAPA Offers Insight on ICD Timing After STEMI

Shelley Wood

September 04, 2019

$Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction Primary results of the PARAGON-HF trial$

Presentation ESC 2019

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

Presenter: Scott D. Solomon

September 01, 2019

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Shelley Wood

September 01, 2019

News Conference News ESC 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

Todd Neale

September 01, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

Advertisement

Stick-on Sensor Predicts Heart-Failure Hospitalizations: Pilot Study

MR Improves in Half of Low-Flow/Low-Gradient AS Patients Undergoing TAVR

Kidney Transplant Boosts CV Functional Reserve

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

Dapagliflozin Has Benefits Across Heart Failure Subgroups

ISCHEMIA: Invasive Strategy No Better Than Meds for CV Events

Off Script: Will ISCHEMIA Answer Our Most Pressing Questions?

Intact Vascular Announces Positive Six-Month Data from TOBA II BTK Clinical Trial During Late-Breaking Session at 2019 VIVA Conference

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

Portico Noninferior to Commercial TAVR Valves in IDE Study

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Stopped Early, DAPA Offers Insight on ICD Timing After STEMI

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content